Morgan Stanley keeps Jazz Pharmaceuticals at Overweight and lifts target to $324
Morgan Stanley kept its Overweight rating on Jazz Pharmaceuticals and raised its price target to $324 from $319, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley reaffirmed its Overweight rating on Jazz Pharmaceuticals and increased its price target to $324 from $319, a rise of 1.6%, according to TradingView, which cites Benzinga data. The new target implies 34.8% upside from the November 12 closing price of $240.37.
Over the past 30 days, the five most recent analyst notes on the company set targets between $275 and $330. Piper Sandler holds the highest target at $330, while JP Morgan, RBC Capital and Barclays published targets of $310, $305 and $275 respectively.
why it matters
Analyst updates like this appear regularly and rarely move a stock on their own. Investors usually weigh them alongside the company's earnings, clinical pipeline news and the overall sentiment in the sector. The spread of price targets suggests that market participants still hold differing views on the stock.
tags
instruments
sources
- Morgan Stanley maintains Jazz Pharmaceuticals at Overweight, raises price target to $324 from $319 — TradingView, 13 November 2026 at 17:51 UTC
- Morgan Stanley maintains BridgeBio Pharma at Overweight, raises price target to $91 from $88 — TradingView, 13 November 2026 at 17:53 UTC
- Morgan Stanley maintains BeOne Medicines at Overweight, raises price target to $476 from $465 — TradingView, 13 November 2026 at 17:56 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗